Parrot David
Known title: Chief Financial OfficerCIK: 0002127908
Parrot David's purchase track record
Parrot David has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/23/2026 | SCTX | $40K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SCTX | ▲ Buy | Open Market | 1,333 | $20K | 7/23/2026 | View on chart |
| SCTX | ▲ Buy | Open Market | 1,333 | $20K | 7/23/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Cathie Wood's ARKG adds Scribe Therapeutics to its biotech holdings
ARK Genomic Revolution ETF (ARKG) increased its position in Scribe Therapeutics, as reported by Yahoo and Benzinga. The addition places Scribe among four biotech names that the fund has recently loaded up on. The stock also appeared in a list of health‑care shares moving in the pre‑market session. This news brings additional attention to the company while the stock shows modest momentum on the chart.
Cathie Wood's ARKG adds Scribe Therapeutics to its biotech holdings. ARK Genomic Revolution ETF (ARKG) increased its position in Scribe Therapeutics, as reported by Yahoo and Benzinga. The addition places Scribe among four biotech names that the fund has recently loaded up on. The stock also appeared in a list of health‑care shares moving in the pre‑market session. This news brings additional attention to the company while the stock shows modest momentum on the chart.